Shots:

• Onconova to receive e $6M upfront including $2M cash- $2M shares & $2M as escrow funding with $45.5M regulatory- development & commercial milestones and royalties on sales. HanX to get an exclusive license for development & commercialization & non-exclusive license to manufacture rigosertib in Greater China
• The focus of the collaboration is to join Onconova’s INSPIRE study and to initiate a study to evaluate the combination of oral rigosertib with azacitidine & POC study for the combination of rigosertib with a PD-1 inhibitor in NSCLC + Ras mutations
• Rigosertib is a targeted anti-cancer therapy- currently being evaluated in P-III INSPIRE trials in patients with HR-MDS with its expected completion in H2’19 and has received ODD for MDS in the US & Europe. Additionally- Onconova collaborated with SymBio & Pint Pharma for rigosertib in Japan- Korea & Latin America respectively

Ref: Onconova | Image:Contract Pharma